These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36173110)

  • 1. Simvastatin Coadministration Modulates the Electrostatically Driven Incorporation of Doxorubicin into Model Lipid and Cell Membranes.
    Bartkowiak A; Nazaruk E; Gajda E; Godlewska M; Gaweł D; Jabłonowska E; Bilewicz R
    ACS Biomater Sci Eng; 2022 Oct; 8(10):4354-4364. PubMed ID: 36173110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of anticancer drugs doxorubicin and idarubicin with lipid monolayers: New insight into the composition, structure and morphology.
    Matyszewska D; Nazaruk E; Campbell RA
    J Colloid Interface Sci; 2021 Jan; 581(Pt A):403-416. PubMed ID: 32771749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporation of simvastatin into lipid membranes: Why deliver a statin in form of inclusion complex with hydrophilic cyclodextrin.
    Bartkowiak A; Matyszewska D; Krzak A; Zaborowska M; Broniatowski M; Bilewicz R
    Colloids Surf B Biointerfaces; 2021 Aug; 204():111784. PubMed ID: 33984617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced antitumour activity of doxorubicin and simvastatin combination loaded nanoemulsion treatment against a Swiss albino mouse model of Ehrlich ascites carcinoma.
    Alkreathy HM; Alkhatib MH; Al Musaddi SA; Balamash KSA; Osman NN; Ahmad A
    Clin Exp Pharmacol Physiol; 2019 May; 46(5):496-505. PubMed ID: 30724380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The influence of charge and lipophilicity of daunorubicin and idarubicin on their penetration of model biological membranes - Langmuir monolayer and electrochemical studies.
    Matyszewska D
    Biochim Biophys Acta Biomembr; 2020 Feb; 1862(2):183104. PubMed ID: 31672546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cubosomal Lipid Formulation for Combination Cancer Treatment: Delivery of a Chemotherapeutic Agent and Complexed α-Particle Emitter
    Cytryniak A; Żelechowska-Matysiak K; Nazaruk E; Bilewicz R; Walczak R; Majka E; Mames A; Bruchertseifer F; Morgenstern A; Bilewicz A; Majkowska-Pilip A
    Mol Pharm; 2022 Aug; 19(8):2818-2831. PubMed ID: 35849547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A liposomal formulation of simvastatin and doxorubicin for improved cardioprotective and anti-cancer effect.
    Bjørnstad R; Reiten IN; Knudsen KS; Schjøtt J; Herfindal L
    Int J Pharm; 2022 Dec; 629():122379. PubMed ID: 36370997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid membranes exposed to dispersions of phytantriol and monoolein cubosomes: Langmuir monolayer and HeLa cell membrane studies.
    Jabłonowska E; Matyszewska D; Nazaruk E; Godlewska M; Gaweł D; Bilewicz R
    Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129738. PubMed ID: 32956751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pH-temperature dual-sensitive nucleolipid-containing stealth liposomes anchored with PEGylated AuNPs for triggering delivery of doxorubicin.
    García MC; Calderón-Montaño JM; Rueda M; Longhi M; Rabasco AM; López-Lázaro M; Prieto-Dapena F; González-Rodríguez ML
    Int J Pharm; 2022 May; 619():121691. PubMed ID: 35331830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-Encapsulation of Simvastatin and Doxorubicin into pH-Sensitive Liposomes Enhances Antitumoral Activity in Breast Cancer Cell Lines.
    Duarte JA; Gomes ER; De Barros ALB; Leite EA
    Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Doxorubicin induces prostate cancer drug resistance by upregulation of ABCG4 through GSH depletion and CREB activation: Relevance of statins in chemosensitization.
    Mallappa S; Neeli PK; Karnewar S; Kotamraju S
    Mol Carcinog; 2019 Jul; 58(7):1118-1133. PubMed ID: 30834613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dynamics simulations of doxorubicin in sphingomyelin-based lipid membranes.
    Siani P; Donadoni E; Ferraro L; Re F; Di Valentin C
    Biochim Biophys Acta Biomembr; 2022 Feb; 1864(1):183763. PubMed ID: 34506799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of alkylphosphocholines with model membranes-the Langmuir monolayer study.
    Wnętrzak A; Lątka K; Dynarowicz-Łątka P
    J Membr Biol; 2013 Jun; 246(6):453-66. PubMed ID: 23673723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
    Krishna R; Mayer LD
    Cancer Res; 1997 Dec; 57(23):5246-53. PubMed ID: 9393743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of membrane models and their composition for islet amyloid polypeptide-membrane aggregation.
    Caillon L; Lequin O; Khemtémourian L
    Biochim Biophys Acta; 2013 Sep; 1828(9):2091-8. PubMed ID: 23707907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. pH dependence of daunorubicin interactions with model DMPC:Cholesterol membranes.
    Matyszewska D; Brzezińska K; Juhaniewicz J; Bilewicz R
    Colloids Surf B Biointerfaces; 2015 Oct; 134():295-303. PubMed ID: 26209780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mZD7349 peptide-conjugated PLGA nanoparticles directed against VCAM-1 for targeted delivery of simvastatin to restore dysfunctional HUVECs.
    Imanparast F; Faramarzi MA; Vatannejad A; Paknejad M; Deiham B; Kobarfard F; Amani A; Doosti M
    Microvasc Res; 2017 Jul; 112():14-19. PubMed ID: 28161429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
    Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
    Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and evaluation of pH-sensitive liposomes constructed by poly(2-ethyl-2-oxazoline)-cholesterol hemisuccinate for doxorubicin delivery.
    Xu H; Hu M; Yu X; Li Y; Fu Y; Zhou X; Zhang D; Li J
    Eur J Pharm Biopharm; 2015 Apr; 91():66-74. PubMed ID: 25660909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.